Joint Action

The first line pain relieving medication recommended in most therapeutic guidelines for osteoarthritis is the anti-inflammatory group of medications. They consistently demonstrate modest effects for relieving pain and improving function, pretty much irrespective of the site of osteoarthritis whether that be the hand, knee or hip. There is a huge variety of anti-inflammatories available, different routes of administration including oral and topical, different dosage strengths along with other elements that influence patient preference. On this episode we discuss: what are non-steroidal anti-inflammatory drugs (NSAIDs) and how do they work, what are the side effects of taking NSAIDs and how often do these occur, how efficacious are NSAIDs for pain relief and much moreProf Ric Day AM (MBBS, FRACP, MD) is internationally and nationally recognised for his research, leadership and advocacy in support of quality use of medicines (QUM). He has been deeply involved in Australia’s National Medicines Policy and the quality use of medicines component culminating in his Chairmanship of the Pharmaceutical Health and Rational Use of Medicines Committee (PHARM) for the Federal Government in 1999-2008. His research focuses on quality use of medicines and methods of enhancing the safe use of medicines using eHealth systems and decision support tools He has published over 600 peer reviewed papers. His current collaborations have lead to significant work investigating the potential of eHealth tools to increase medication safety but he has other significant areas of research. Prof Day is a committed undergraduate & post-graduate teacher & research mentor. Prof Day has received many awards, including Member of the Order of Australia AM. RESOURCESNPS MedicinewiseArthritis AustraliaThis Way UpCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Osteoarthritis is an extraordinarily prevalent and disabling disease. The prevalence appears to be increasing, in large part compounded by the ageing of the population but also with major contributions from demographic shifts as it relates to obesity are leading to increasing numbers of people with osteoarthritis. The two biggest risk factors for knee osteoarthritis are obesity and overweight and joint injury. They account for approximately 75% of a person’s likelihood of developing osteoarthritis of the knee. Both are eminently modifiable but from a public health perspective, we do very little if anything about modifying either. On this episode we discuss: risk factors for developing osteoarthritis, how much weight to lose to reduce their risk of developing osteoarthritis, the effects of weight loss on osteoarthritis and much more. Dr Jos Runhaar is an Assistant Professor at the Department of General Practice of Erasmus MC. NetherlandsHe was trained as Human Movement Scientist at the Vrije University Amsterdam. For his PhD, he performed the first ever trial on the primary prevention of osteoarthritis, supervised by Prof. Bierma-Zeinstra and Prof. Koes. The research direction of Dr. Runhaar aims to improve the diagnosis and treatment of musculoskeletal disorders by general practitioners and physiotherapists and to shift the treatment of musculoskeletal disorders to the early disease phase. RESOURCESJournal articlesWhat if we prevent obesity? Risk reduction in knee osteoarthritis estimated through a meta-analysis of observational studiesCurrent evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysisTo what extent is severe osteoarthritis preventable? Occupational and non-occupational risk factors for knee and hip osteoarthritisPrevention of Incident Knee Osteoarthritis by Moderate Weight Loss in Overweight and Obese FemalesLong-term effects of a randomized, controlled, tailor-made weight-loss intervention in primary care on the health and lifestyle of overweight and obese womenPredicting Knee Pain and Knee Osteoarthritis Among Overweight WomenCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! :) Hosted on Acast. See acast.com/privacy for more information.

Current management approaches for osteoarthritis are usually targeted to symptoms. One way to mitigate the epidemic of osteoarthritis is to modify both its structural progression and symptomatic consequences in tandem a method known as disease modification, as distinct from symptom modification. These could potentially slow the speed of disease progression, completely halted or in an ideal world reverse the disease and regenerate the target tissue. At present, despite a number of positive trials there are no drugs that have garnered regulatory approval for this indication. On this week's episode we discuss: what is disease modification, what have the clinical trials shown, what will the future of DMOADs look like and much more.Christoph Ladel is working as Translational Medicine Expert. Most recent position was as team lead in the global clinical development department in Merck Healthcare KGaA (Darmstadt, Germany). In his role he was involved in design and execution of clinical studies from phase 1 to phase 3. Special responsibility was in the field of biomarker and imaging (MRI and x-ray) read-outs in clinical studies, mainly in osteoarthritis. He contributed to the respective teams to analyze data and to develop further stratification strategies based on biomarkers (incl. imaging) for studies in osteoarthritis. Christoph trained as an immunologist with a PhD in immunopharmacology and immunotoxicology Dr Ladel has worked in different companies and different countries. Over the >15 years he was part of project teams or team leader in different projects for the discovery and development of therapies in osteoarthritis. Christoph is an internationally recognized scientist and has authored > 50 scientific peer reviewed publications and is co-inventor in more than 10 patents in the field of clinical strategies for osteoarthritis.RESOURCESDavid's presentation on DMOADS for the Arthritis Web Seminar Series at UHNWikipedia page on DMOADSJournal articlesCurrent status and future prospects for disease modification in osteoarthritisIntra-articular therapies for osteoarthritisEmerging drugs for the treatment of osteoarthritisCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Elena Losina, an expert in the economic burden of osteoarthritis, discusses the high costs of living with OA, including direct healthcare expenses and lost productivity. She emphasizes the need for cost-effective treatments and efficient healthcare resource allocation to optimize outcomes for individuals with osteoarthritis.

Expert in hand osteoarthritis, Margreet Kloppenburg, talks about the neglected disease, diagnostic criteria, and management options. Discussions include systemic factors, treatment efficacy, steroid injections debate, and recommendations for managing hand osteoarthritis with a multidisciplinary approach.

Foot osteoarthritis affects one in six adults over the age of 50. It is associated with restricted mobility, disability, poor balance, risk of falling and accounts for a substantial number of healthcare consultations. Due to this, there is an increasing interest in research into foot osteoarthritis and we are learning more about foot osteoarthritis and it's prevalence, risk factors and treatments for this condition. Listen to this episode of Joint Action to learn more about foot osteoarthritis with Professor Hylton Menz. On this episode we discuss: the prevalence of foot osteoarthritishow foot osteoarthritis is diagnosedcurrent research into foot osteoarthritis appropriate treatment for foot osteoarthritis (including footwear)Professor Hylton Menz is a podiatrist who graduated with first class Honours and the University Medal from La Trobe University in 1993, and completed his PhD focusing on gait patterns, balance and falls at the University of NSW in 2002. He is currently a National Health and Medical Research Council of Australia Fellow. Professor Menz's broad research disciplines are human movement, rehabilitation and rheumatology, with a particular focus on musculoskeletal foot problems in older people. His research extends from laboratory-based biomechanical studies through to analysis of epidemiological datasets and the conduct of clinical trials. Professor Menz has published over 300 papers in podiatry, gerontology, rheumatology and biomechanics journals. Professor Menz's current research focuses on the epidemiology and management of foot disorders in older people, with a particular emphasis on osteoarthritis.RESOURCESAustralian Podiatry Association webpageCollege of Podiatry UK webpageArthritis Australia webpageCONNECT WITH HYLTONTwitterWebpageCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

On this special episode of Joint Action, we have the privilege of hearing from Tom Buttel and his journey with osteoarthritis. Hear Tom's story and learn how he manages his osteoarthritis to continue living an active lifestyle. We hope that by sharing Tom's story, we are able to motivate and stimulate change in others. On this episode we discuss:the development of Tom's osteoarthritis management/strategies to control the symptoms of osteoarthritisperspectives of different health care providers and the management of osteoarthritisand much more!CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Expert Tim Hewett discusses ACL injuries and osteoarthritis, highlighting risk factors, neuromuscular imbalances, training programs, and reducing reinjury. Insights on athlete injury prediction and prevention, intrinsic factors influencing ACL tear risk, and interventions to prevent joint injuries. Emphasizes the importance of educating about long-term consequences of ACL injuries and promoting physical activity in individuals at risk for osteoarthritis.

Dr. Leigh Callahan is the Director of the Osteoarthritis Action Alliance (OAAA). She is also an epidemiologist and outcomes researcher who, for more than 30 years, has worked in musculoskeletal outcomes research.Her research has focused on predictors of outcomes and quality of life in individuals with osteoarthritis (OA) and rheumatoid arthritis (RA), patient-reported outcomes and measurement, physical activity and arthritis, social determinants and health outcomes, health literacy, and complementary and alternative medicine use in rheumatic diseases.She is also Professor of Medicine and Associate Director of the Thurston Arthritis Research Center, as well as Director of the UNC Core Center of Clinical Research that is focused on enhancing the design and conduct of clinical studies in rheumatic and musculoskeletal diseases.On this episode we discuss: the work of the Osteoarthritis Action Alliance (OAAA), and their future directionsResources:The OAAA webpage Hosted on Acast. See acast.com/privacy for more information.

Dr. Zhang, a senior epidemiologist, discusses racial differences in osteoarthritis prevalence, disparities in treatment outcomes, and the importance of addressing risk factors. The podcast also explores the impact of race and ethnicity on pain reporting, collaboration in Boston, and maintaining hope during challenging times.